Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all

被引:1
作者
Chin, W. K. [1 ]
机构
[1] Monash Univ Malaysia, Sch Pharm, Subang Jaya, Malaysia
关键词
atopic dermatitis; leukotriene; leukotriene receptor antagonist; montelukast; off-label use; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; THERAPEUTIC AGENT; MONTELUKAST; MODERATE; EFFICACY; CHILDREN;
D O I
10.1111/jcpt.12648
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and ObjectiveLiterature evidence suggests leukotriene involvement in the pathogenesis of atopic dermatitis. This article aimed to discuss whether the off-label use of montelukast, a leukotriene receptor antagonist, is justifiable for the treatment of atopic dermatitis. CommentMost non-randomized studies supported the use of montelukast for atopic dermatitis treatment. However, evidence from these studies should be interpreted with caution as it is relatively weak due to the absence of randomization, control groups and blinding processes, subjecting the results to high risk of selection and reporting biases. The inconsistent findings across RCTs may be related to the limited number of patients, nuances in study designs, varying severity of disease and the concomitant use of steroids in some of the studies. What is new and ConclusionCurrent literature evidence is limited to rationally support the use of montelukast in atopic dermatitis treatment. For now, the conventional treatments should be preferred in the clinical setting.
引用
收藏
页码:159 / 162
页数:4
相关论文
共 30 条
[1]   Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status [J].
Adamek-Guzik, T ;
Guzik, TJ ;
Czerniawska-Mysik, G ;
Korpanty, G ;
Mastalerz, L ;
Radwan, J ;
Szczeklik, A .
ALLERGY, 2002, 57 (08) :732-736
[2]  
Angelova-Fischer I, 2005, ACTA DERMATOVEN ALP, V14, P115
[3]  
[Anonymous], CURR PEDIAT RES
[4]  
Biswas P, 2001, INT J CLIN PHARM TH, V39, P529
[5]  
Capella GL, 2001, EUR J DERMATOL, V11, P209
[6]   Montelukast causes prolonged, potent leukotriene D-4-receptor antagonism in the airways of patients with asthma [J].
DeLepeleire, I ;
Reiss, TF ;
Rochette, F ;
Botto, A ;
Zhang, J ;
Kundu, S ;
Decramer, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (01) :83-92
[7]  
Dhar Sandipan, 2005, Indian J Dermatol Venereol Leprol, V71, P246
[8]   Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults [J].
Eustachio, N ;
Alessandro, P ;
Margherita, F ;
Antonio, F ;
Tursi, A .
ACTA DERMATO-VENEREOLOGICA, 2002, 82 (04) :297-298
[9]   A double-blind, placebo-controlled trial of montelukast in adult atopic eczema [J].
Friedmann, P. S. ;
Palmer, R. ;
Tan, E. ;
Ogboli, M. ;
Barclay, G. ;
Hotchkiss, K. ;
Berth-Jones, J. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2007, 37 (10) :1536-1540
[10]   Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis [J].
Hon, KLE ;
Leung, TF ;
Ma, KC ;
Wong, Y ;
Fok, TF .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2005, 16 (01) :15-18